New guidelines for pregnancy care in multiple sclerosis, drawn up by a panel of UK experts, have been published this week.
They aim to reduce uncertainty about treatments that are safe and appropriate for pregnant and breastfeeding women with MS, and for couples affected by MS who are planning a pregnancy.
MS is usually diagnosed among 20-40 year olds, two thirds of whom are women. Around this age, both men and women might be planning to have children. At the same time, it is becoming increasingly clear that disease modifying drugs (DMDs) should be started as early as possible. Delaying DMD treatment until after having a family can lead to irreversible disability in the long term. For this reason, it makes sense to start discussing family planning and pregnancy early after diagnosis, alongside discussions about DMDs, if appropriate.
However, there is limited evidence available to guide these discussions, and so the MS Trust and a group of very experienced health professionals set out to develop a set of consensus guidelines to bring clarity to this area. The guidelines have been endorsed by the Association of British Neurologists, and have been reviewed by a panel of MS specialist nurses, neurologists, obstetricians, midwives and people with MS as part of the development process.
The guidelines bring together evidence from drug specific pregnancy registers as well as published peer reviewed research. They cover pre-pregnancy counselling and DMDs for men and women, MS management during pregnancy, delivery and anaesthetic options. The guidelines also give advice for the period after birth, for breastfeeding and for the use of DMDs after the birth.
We hope that the publication of these guidelines will enable health professionals to provide more informed guidance, support and care to people with MS when they are planning a family as well as during pregnancy and the post-natal period.
- Megan Roberts, Health Professionals Programme Manager, MS Trust
- Practical Neurology 2019;19:106-114. Full article UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines
Pregnancy and MS
For most women, MS does not make any significant difference to their pregnancy. Find out how to manage MS throughout your pregnancy.
DMT use in fathers to be
3 June 2014
A study examining the outcomes of pregnancies fathered by a man with multiple sclerosis taking a disease modifying drug.
Disease modifying drugs (DMDs)
DMDs are a group of treatments for people with relapsing MS which reduce the number and severity of any relapses you might experience.
New study provides strong evidence for role of Epstein Barr virus as a trigger for multiple sclerosis
14 Jan 2022 - 00:00
New research has provided evidence that infection with the Epstein Barr virus acts as a trigger for people to develop MS.
The PANORAMIC trial for Covid-19 treatment
23 Dec 2021 - 00:00
If you are not eligible to receive Covid-19 treatment automatically on the basis of increased risk, you may be able to get antiviral medication through the PANORAMIC clinical trial.
Ponvory (ponesimod) approved for relapsing remitting MS in England and Wales
23 Dec 2021 - 00:00
The MS Trust is delighted that Ponvory (ponesimod) has been approved in England and Wales for people with active relapsing remitting multiple sclerosis.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.